Kintor Pharmaceutical Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNTPF research report →
Price Chart
About the company
Kintor Pharmaceutical Limited is a clinical-stage biotechnology firm dedicated to the development and commercialization of a diverse pipeline of small molecule and biologic treatments. Its primary focus is on addressing androgen-receptor-related conditions where current medical options are lacking, serving patients both within the People's Republic of China and globally. The company's innovative pipeline features several key candidates, such as Proxalutamide, a next-generation androgen receptor (AR) antagonist currently being investigated for metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19.
- CEO
- Youzhi Tong
- IPO
- 2020
- Employees
- 123
- HQ
- Suzhou, JS, CN
Get TickerSpark's AI analysis on KNTPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $113.24M
- P/E
- -3.34
- PEG
- 0.86
- P/S
- 8.28
- P/B
- 6.19
- EV/EBITDA
- -4.67
- Div Yield
- 0.00%
- Gross Margin
- 12.57%
- Op Margin
- -256.09%
- Net Margin
- -244.44%
- ROE
- -129.93%
- ROIC
- -71.63%
Latest fiscal year · YoY change
- Revenue
- $31.84M+536.8%
- Gross Profit
- $-24,524,362-418.5%
- Op Income
- $-197,355,170
- Net Income
- $-194,943,066-25.5%
- EPS
- $-0.43-19.4%
- OCF Growth
- +14.7%
- FCF Growth
- +15.1%
- 52W High
- $0.57
- 52W Low
- $0.17
- 50D MA
- $0.23
- 200D MA
- $0.31
- Beta
- -0.57
- RSI (14)
- 63
- Avg Volume
- 3.87K
No earnings-call transcripts are available for KNTPF yet.
- Free Float
- 80.8%
- Shares Outstanding
- 468.90M
- Float Shares
- 378.65M
Our KNTPF coverage
Recent articles, reports, and earnings notes.
No research on KNTPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KNTPF report →Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
prnewswire.com · Oct 11
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
prnewswire.com · Aug 22
Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA
prnewswire.com · Jul 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.